

Clinical Characteristics of SARS-CoV-2 Omicron Cases in Pune, Maharashtra, India

Review began 03/22/2023
Review ended 03/29/2023
Published 04/02/2023

© Copyright 2023

Borse et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Rohidas Borse¹, Rajesh P. Karyakarte², Rashmita Das², Sushma Yanamandra², Sonali Salvi¹, Harshal Bhitkar¹, Sanjay Mundhe¹, Dhananjay Ogale¹, Nagnath Radewad¹, Suvarna Joshi², Krishanpal Karmodiya³

1. Internal Medicine, Byramjee Jeejeebhoy Government Medical College & Sassoon General Hospitals, Pune, IND 2. Microbiology, Byramjee Jeejeebhoy Government Medical College & Sassoon General Hospitals, Pune, IND 3. Department of Biology, Indian Institute of Science Education and Research, Pune, IND

Corresponding author: Rajesh P. Karyakarte, karyakarte@hotmail.com

Abstract

Background

The SARS-CoV-2 Omicron variant, within two months of its detection, replaced the Delta variant to become the dominant circulating variant globally. Therefore, it is essential to understand the characteristics of the disease caused by the variant and its impact on vaccination.

Methods

A total of 165 confirmed Omicron cases attending a tertiary care hospital in Pune, Maharashtra, between December 2021 to February 2022 were studied. Their demographic, clinical, and immunization history was recorded.

Results

Among the 165 cases, 7.88% were B.1.1.529 Omicron cases, 25.45% were BA.1 Omicron cases, and 66.67% were BA.2 Omicron cases. Of these 165 patients, 146 (88.48%) were discharged after treatment, 12 (7.27%) died during hospitalization, and seven (4.24%) were brought dead. The presence of one or more comorbid conditions was seen in 15.15%, of which diabetes mellitus and hypertension (28% each) were the most common conditions. Older age (greater than 60 years), an important risk factor for poor outcomes, was present in 9.1% of cases. Among the 165 cases, vaccination with at least one dose of vaccine was found in 80.61% of cases. Out of 165 cases, clinical data was available for 158 cases. Of these 158 cases, 86.71% had symptoms, and 13.29% were asymptomatic. Fever, followed by cough, myalgia, runny nose, and headache, were the most common presenting symptoms. The mean duration of illness was 2.69 days, with 91.14% of cases having the illness for less than five days, and 89.24% of cases had a National Early Warning Score (NEWS) of 1-4, suggesting a good prognosis. In 93.90% of cases, the chest X-ray findings were normal. Of the 158 cases, 92.41% of cases recovered with supportive treatment, and only 7.59% of cases required oxygen therapy.

Conclusion

The current study shows that the Omicron variant caused mild disease with reduced need for hospital admission and oxygen therapy in India.

Categories: Internal Medicine, Infectious Disease

Keywords: variant of concern, clinical and laboratory characteristics, covid-19, omicron variant, sars-cov-2

Introduction

On 24th November 2021, a novel SARS-CoV-2 variant was first reported from South Africa [1]. The variant was initially identified as Pango lineage B.1.1.529 and was designated as Omicron, a Variant of Concern (VOC) by the World Health Organization on 26th November 2021. This highly mutated SARS-CoV-2 variant had nearly 50 mutations in its genome compared to the original SARS-CoV-2 virus isolated in Wuhan, China. Of these mutations, around 26-30 mutations are of particular interest as they are in the spike protein region, of which 15 were in its receptor-binding domain (RBD) [2]. Since its first identification, the variant has spread rapidly worldwide and accounts for 99% of sequences reported globally [3].

Omicron is a highly transmissible variant with an effective reproduction number 3.19 (95% CI 2.82-3.61) times greater than Delta's. This property accounts for its rapid increase in numbers and higher transmissibility, thus displacing the prevailing Delta variant [4]. Various early studies have shown that extensive immune escape and reduced vaccine effectiveness of the Omicron variant have led to its higher transmission rate. Preliminary studies suggest that the variant causes less severe disease with milder

How to cite this article

Borse R, Karyakarte R P, Das R, et al. (April 02, 2023) Clinical Characteristics of SARS-CoV-2 Omicron Cases in Pune, Maharashtra, India. Cureus 15(4): e37032. DOI 10.7759/cureus.37032

clinical manifestations such as rhinorrhea, sore throat, and headache. Though infections due to the Omicron variant have surged worldwide, it has not led to increased hospitalization in the same way as in the earlier Delta wave [5]. Many demographic studies with evidence of reduced disease severity and hospitalization due to the Omicron variant have been shared by countries with diverse levels of population immunity.

India saw an upsurge in coronavirus disease (COVID-19) cases driven by the Omicron variant in the last week of December 2021 [6]. Omicron emerged during the period when the country already had 57% of the population vaccinated with at least one vaccine dose [7]. In the context of the above-mentioned scenario, the present study describes the epidemiological, clinical characteristics, and outcomes of Omicron-confirmed cases in a tertiary care hospital in Pune, Maharashtra, India.

Materials And Methods

This clinical study was carried out at the Department of Medicine in collaboration with the Department of Microbiology at Byramjee Jeejeebhoy Government Medical College (BJGMC), Pune, Maharashtra, India. The study falls within the research activities approved by the Institutional Ethics Committee, BJGMC, Pune, Maharashtra (BJGMC/IEC/Pharmac/ND-Dept 0721233-233, dated 15-09-2021).

Sample acquisition for SARS-CoV-2 whole genome sequencing

RT-PCR-positive nasopharyngeal samples of patients attending Sassoon Hospital between December 2021 and February 2022 were collected in a viral transport medium (VTM). The samples were transported to the sequencing laboratory in the Department of Microbiology, BJGMC, Pune, maintaining a cold chain between 2-8°C and were stored at -80°C until further processing. Samples with a cycle threshold value (Ct value) less than 25 were processed for SARS-CoV-2 whole-genome sequencing.

The extracted RNA samples were sent to the Indian Institute of Science Education and Research (IISER), Pune, and the Centre of Excellence for Genomics, Department of Microbiology, BJGMC for SARS-CoV-2 whole-genome sequencing and lineage analysis.

Library preparation, next-generation sequencings, and lineage analysis

Libraries for COVID-19 were prepared using the defined protocol for Illumina COVIDseq RUO test kits (Illumina Inc., San Diego, CA) at IISER, Pune, and Rapid barcoding and Midnight RT-PCR Expansion kits (Midnight Protocol, Oxford Nanopore Technologies, Littlemore, United Kingdom) at BJGMC. Sequencing was performed using the NextSeq 500 sequencer (Illumina Inc.) at IISER and GridION sequencer (Oxford Nanopore Technologies) at BJGMC. Lineage identification and clade analysis were performed using Pangolin (<https://github.com/hCoV-2019/pangolin>) and Nextclade software (<https://clades.nextstrain.org/>).

Data collection and analysis

Demographic characteristics and the clinical findings of Omicron cases were collected from medical and laboratory records maintained by the medical record section of the hospital. The data were entered in Microsoft Excel, and analysis was done using the JMP statistical software, version 13.0.0 (SAS Institute, Cary, NC). A p-value of less than 0.05 (typically ≤ 0.05) was considered a statistically significant result.

Results

A total of 165 confirmed Omicron cases were studied between December 2021 and February 2022. Among the 165 cases, 7.88% were B.1.1.529, 25.45% were BA.1, and 66.67% were BA.2 cases. Of these 165 cases, 146 (88.48%) were discharged after treatment, 12 (7.27%) died during hospitalization, and seven (4.24%) were brought in dead. Figure 1 and Table 1 show the relationship between the Omicron variants and the outcome of the disease. Among the 19 patients who died, one (5.26%) had a BA.1 infection, and 18 (94.74%) had a BA.2 infection (seven (38.89%) were brought in dead, and 11 (61.11%) died during hospitalization).




FIGURE 1: Mosaic plot showing Pangolin lineage versus the outcome of confirmed Omicron cases

| Test | ChiSquare (χ2) | Prob>ChiSq (p-value) |
|------------------|----------------|----------------------|
| Likelihood Ratio | 10.37 | 0.0056 |
| Pearson | 7.67 | 0.0216 |

TABLE 1: Chi-square test results for goodness of fit showing Pangolin lineage versus the outcome of confirmed Omicron cases

Demographic characteristics of COVID-19 cases infected with the Omicron variant of SARS-CoV-2

The demographic characteristics of 165 confirmed Omicron cases are shown in Table 2. Males (56.97%) were more affected than females (43.03%), with male to female ratio of 1.3: 1. The mean age of the study population was 36.51 (standard deviation = 17.02, 95% CI = 33.89 to 39.13). The age group 21 to 40 years were predominantly affected, followed by 41 to 60 years. Older age (greater than 60 years), an important risk factor for poor outcome, was present in 15/165 (9.1%) of cases. Figure 2 and Table 3 show the relationship between age and disease outcome. The presence of one or more comorbid conditions was seen in 15.15% of cases, diabetes mellitus (28%), hypertension (28%), obesity (16%), and interstitial heart disease (16%) were the most common conditions. Of the 165 cases, 81.82% were vaccinated with at least one dose of the COVID-19 vaccine (92.59% were vaccinated with two doses, and 7.41% were vaccinated with one dose of the vaccine), and 16.36% of the cases were unvaccinated. Figure 3 and Table 4 show the relationship between the vaccination status and the outcome of Omicron-confirmed cases.

| Demographic characteristics | The number of cases survived (%) | Number of cases that died during their stay in the hospital (%) | Number of cases brought in dead to the hospital (%) | Total (%) | p-value |
|-----------------------------|----------------------------------|-----------------------------------------------------------------|-----------------------------------------------------|------------|----------|
| Age group (In years) | | | | | < 0.0001 |
| 0-20 | 14 (9.59%) | 01 (8.33%) | 01 (14.29%) | 16 (9.70%) | |

| | | | | | |
|------------------------------------------------|--------------|-------------|-------------|-----------------|--|
| 21-40 | 87 (59.59%) | 01 (8.33%) | 00 (00%) | 88 (53.33%) | |
| 41-60 | 39 (26.72%) | 04 (33.33%) | 03 (42.86%) | 46 (27.88%) | |
| 61-80 | 05 (3.42%) | 06 (50%) | 02 (28.57%) | 13 (7.88%) | |
| >80 | 01 (0.68%) | 00 (00%) | 01 (14.29%) | 02 (1.21%) | |
| Gender | | | | | |
| Male | 82 (56.16%) | 07 (58.33%) | 05 (71.43%) | 94 (56.97%) | |
| Female | 64 (43.84%) | 05 (41.67%) | 02 (28.57%) | 71 (43.03%) | |
| Area of Residence | | | | | |
| Rural | 12 (8.22%) | 03 (25%) | - | 15 (9.09%) | |
| Urban | 134 (91.78%) | 09 (75%) | - | 143 (86.67%) | |
| Data not available | 00 (00%) | 00 (00%) | 07 (100%) | 07 (4.24%) | |
| Marital Status | | | | | |
| Married | 69 (47.26%) | 10 (83.33%) | 07 (100%) | 86 (52.12%) | |
| Unmarried | 77 (52.74%) | 02 (16.67%) | 00 (00%) | 79 (47.88%) | |
| Socio-economic Status | | | | | |
| Average | 38 (26.03%) | 00 (00%) | 00 (00%) | 38 (23.03%) | |
| Poor | 52 (35.62%) | 12 (100%) | 07 (100%) | 71 (43.03%) | |
| Data not available | 14 (9.59%) | 00 (00%) | 00 (00%) | 14 (8.48%) | |
| Student | 42 (28.77%) | 00 (00%) | 00 (00%) | 42 (25.46%) | |
| Comorbidity Score | | | | | |
| No comorbid conditions present | 133 (91.10%) | 04 (33.33%) | 03 (42.86%) | 140 (84.85%) | |
| Presence of one or more condition | 13 (8.90%) | 08 (66.67%) | 04 (57.14%) | 25 (15.15%) | |
| Old age (Greater than 60 years- a risk factor) | 06 (46.15%) | 06 (75%) | 03 (75%) | 15 (60%) | |
| Diabetes Mellitus (DM) | 02 (15.38%) | 03 (37.50%) | 02 (50%) | 07 (28%) | |
| Hypertension (HTN) | 01 (7.69%) | 05 (62.50%) | 01 (25%) | 07 (28%) | |
| Obesity | 04 (30.77%) | 00 (00%) | 00 (00%) | 04 (16%) | |
| Interstitial Heart Disease (IHD) | 01 (7.69%) | 03 (37.50%) | 00 (00%) | 04 (16%) | |
| Liver Cirrhosis | 00 (00%) | 01 (12.50%) | 01 (25%) | 02 | |

| | | | | | |
|------------------------------|--------------|-------------|-------------|--------------|----------|
| | | | | (08%) | |
| Haematological Disorder | 00 (00%) | 02 (25%) | 00 (00%) | 02 (08%) | |
| Pulmonary Tuberculosis | 02 (15.38%) | 00 (00%) | 00 (00%) | 02 (08%) | |
| Pulmonary venous disorder | 00 (00%) | 01 (12.50%) | 00 (00%) | 01 (04%) | |
| Chronic Kidney Disorder | 00 (00%) | 01 (12.50%) | 00 (00%) | 01 (04%) | |
| Cerebrovascular disorder | 00 (00%) | 01 (12.50%) | 00 (00%) | 01 (04%) | |
| Seizure disorder | 00 (00%) | 01 (12.50%) | 00 (00%) | 01 (04%) | |
| Psychiatric Illness | 01 (7.69%) | 00 (00%) | 00 (00%) | 01 (04%) | |
| Rheumatological Disorder | 01 (7.69%) | 00 (00%) | 00 (00%) | 01 (04%) | |
| Malignancy | 00 (00%) | 01 (12.50%) | 00 (00%) | 01 (04%) | |
| HIV | 01 (7.69%) | 00 (00%) | 00 (00%) | 01 (04%) | |
| Vaccination Status | | | | | < 0.0001 |
| Vaccinated | 127 (86.99%) | 06 (50%) | 02 (28.57%) | 135 (81.82%) | |
| With one dose | 07 (5.51%) | 01 (16.67%) | 02 (100%) | 10 (7.41%) | |
| With two doses | 120 (94.49%) | 05 (83.33%) | 00 (00%) | 125 (92.59%) | |
| Not Vaccinated | 19 (13.01%) | 06 (50%) | 02 (28.57%) | 27 (16.36%) | |
| Data not available | 00 (00%) | 00 (0.00%) | 02 (28.57%) | 02 (1.21%) | |
| Not eligible for vaccination | 00 (00%) | 00 (00%) | 01 (14.29%) | 01 (0.61%) | |

TABLE 2: Demographic characteristics of 165 Omicron cases




FIGURE 2: Mosaic plot showing the relationship between age and the outcome of confirmed Omicron cases

| Test | ChiSquare (χ^2) | Prob>ChiSq (p-value) |
|------------------|------------------------|----------------------|
| Likelihood Ratio | 39.208 | <0.0001 |
| Pearson | 55.154 | <0.0001 |

TABLE 3: Chi-square test results for goodness of fit showing the relationship between age and the outcome of disease




FIGURE 3: Mosaic plot showing the relationship between vaccination status and the outcome of confirmed Omicron cases

| Test | ChiSquare (χ2) | Prob>ChiSq (p-value) |
|------------------|----------------|----------------------|
| Likelihood Ratio | 17.43 | 0.0002 |
| Pearson | 21.24 | <0.0001 |

TABLE 4: Chi-square test results for goodness of fit showing the relationship between vaccination status and the outcome of confirmed Omicron cases

Clinical profile of COVID-19 cases infected with the Omicron variant of SARS-CoV-2

Out of 165 cases, the clinical characteristics of 158 (95.76%) Omicron cases could be recorded as the remaining seven cases were brought in dead (Table 5). Of these 158 cases, 86.71% had symptomatic disease, and 13.29% had an asymptomatic infection. Fever (67.72%) was the most common presenting symptom, followed by cough (40.51%), myalgia (35.44%), runny nose (22.78%), and headache (15.82%). The duration of illness was less than five days in 91.14% of cases, and only in 8.86% of cases the illness lasted for more than a week. Figure 4 and Table 6 show the relationship between the duration of illness to Omicron variants. The mean duration of illness on admission was 2.69 days (standard deviation = 2.12, 95% CI = 2.36 to 3.02). Table 7 describes the biochemical and hematological parameters of the hospitalized Omicron cases.

| Clinical characteristics | Number of cases survived (%) | Number of cases that died during their stay in the hospital (%) | Total (%) | p-value |
|--------------------------|------------------------------|-----------------------------------------------------------------|-------------|---------|
| Symptom status | | | | |
| Asymptomatic | 21 (14.38%) | 00 (00%) | 21 (13.29%) | |
| Symptomatic | 125 (85.62%) | 12 (100%) | 137 | |

| | | | | |
|-----------------------------------------------|--------------|-------------|-----------------|-------------|
| | | | (86.71%) | |
| Initial presenting symptoms | | | | |
| Fever | 103 (70.55%) | 04 (33.33%) | 107 (67.72%) | |
| Anosmia | 00 (00%) | 07 (58.33%) | 07 (4.43%) | |
| Ageusia | 00 (00%) | 08 (66.67%) | 08 (5.06%) | |
| Rhinorrhoea | 36 (24.66%) | 00 (00%) | 36 (22.78%) | |
| Cough | 60 (41.10%) | 04 (33.33%) | 64 (40.51%) | |
| Breathlessness | 06 (4.11%) | 08 (66.67%) | 14 (8.86%) | |
| Headache | 25 (17.12%) | 00 (00%) | 25 (15.82%) | |
| Myalgia | 56 (38.36%) | 00 (00%) | 56 (35.44%) | |
| Vomiting | 03 (2.05%) | 00 (00%) | 03 (1.90%) | |
| Fatigue/ Weakness | 15 (10.27%) | 02 (16.67%) | 17 (10.76%) | |
| Abdominal Pain | 00 (00%) | 01 (8.33%) | 01 (0.63%) | |
| Duration of Illness | | | | |
| Less than 5 days | 139 (95.21%) | 05 (41.67%) | 144 (91.14%) | |
| More than 6 days | 07 (4.79%) | 07 (58.33%) | 14 (8.86%) | |
| NEWS score | | | | 0.3072 |
| 1 to 4 | 139 (95.21%) | 02 (16.67%) | 141 (89.24%) | |
| 5 to 8 | 07 (4.79%) | 07 (58.33%) | 14 (8.86%) | |
| More than 9 | 00 (00%) | 03 (25%) | 03 (1.90%) | |
| Number of Organ systems involvement | | | | < 0.0001 |
| No Organ system involvement | 102(69.86%) | 00 (00%) | 102 (64.56%) | |
| The involvement of one or more organ systems | 44 (30.14%) | 12 (100%) | 56 (35.44%) | |
| Single-system involvement | 25 (56.82%) | 00 (00%) | 25 (44.64%) | |
| Two-system involvement | 13 (29.55%) | 00 (00%) | 13 (23.21%) | |
| Three or more systems involvement | 06 (13.64%) | 12 (100%) | 18 (32.14%) | |
| Chest X-ray findings in admitted cases (n=82) | | | | |

| | | | | |
|----------------------------------------------------------------------------------|-------------|-------------|-----------------|--|
| Normal X-ray findings | 67 (100%) | 10 (66.67%) | 77 (93.90%) | |
| Abnormal findings | 00 (00%) | 05 (33.33%) | 05 (6.10%) | |
| Pulmonary infiltrates | 00 (00%) | 02 (40%) | 02 (40%) | |
| Pulmonary oedema | 00 (00%) | 03 (60%) | 03 (60%) | |
| Type of treatment given | | | | |
| Conservative treatment | 146 (100%) | 00 (00%) | 146 (92.41%) | |
| In-patient department | 70 (47.95%) | 00 (00%) | 70 (47.95%) | |
| Out-patient department | 76 (52.05%) | 00 (00%) | 76 (52.05%) | |
| Need for oxygen therapy | 00 (00%) | 12 (100%) | 12 (7.59%) | |
| Duration of hospital stay among cases who were given standard care (n=82) | | | | |
| Less than 24 hours | 00 (00%) | 01 (8.33%) | 01 (1.22%) | |
| 1 day to 2 days | 07 (10%) | 02 (16.67%) | 09 (10.98%) | |
| 3 days to 4 days | 25 (35.71%) | 00 (00%) | 25 (30.49%) | |
| 5 days to 9 days | 36 (51.43%) | 04 (33.33%) | 40 (48.78%) | |
| Greater than 10 days | 02 (2.86%) | 05 (41.67%) | 07 (8.53%) | |
| Duration of non-invasive ventilation among cases requiring oxygen therapy (n=12) | | | | |
| Less than 24 hours | 00 (00%) | 04 (33.33%) | 04 (33.33%) | |
| 1 day to 2 days | 00 (00%) | 05 (41.67%) | 05 (41.67%) | |
| Greater than 3 days | 00 (00%) | 03 (25%) | 03 (25%) | |
| Duration of invasive ventilation among cases requiring oxygen therapy (n=12) | | | | |
| Less than 6 hours | 00 (00%) | 02 (16.67%) | 02 (16.67%) | |
| 6 hours to 12 hours | 00 (00%) | 05 (41.67%) | 05 (41.67%) | |
| 12 hours to less than 24 hours | 00 (00%) | 01 (8.33%) | 01 (8.33%) | |
| 1 day to 2 days | 00 (00%) | 02 (16.67%) | 02 (16.67%) | |
| 3 days to 7 days | 00 (00%) | 02 (16.67%) | 02 (16.67%) | |

TABLE 5: Clinical characteristics of 158 Omicron cases




FIGURE 4: Mosaic plot showing the duration of illness versus Omicron variant

Duration of Illness (DOI)

| Test | ChiSquare (χ^2) | Prob>ChiSq (p-value) |
|------------------|------------------------|----------------------|
| Likelihood Ratio | 11.046 | 0.026 |
| Pearson | 8.44 | 0.077 |

TABLE 6: Chi-square test results for goodness of fit showing the relationship between duration of illness versus Omicron variant

| Laboratory Parameters | Reference range | Number of cases | Mean value | Standard deviation | Upper and lower 95% CI |
|--------------------------|-----------------|-----------------|------------|--------------------|------------------------|
| Biochemical Parameters | | | | | |
| Liver Function Tests | | | | | |
| Total Bilirubin (n= 139) | | | 0.60 | 0.47 | 0.68 – 0.52 |
| Low | | 00 | | | |
| Normal | 0.3 – 1.0 mg/dL | 128 | | | |
| High | | 11 | | | |
| Direct Bilirubin (n=123) | | | 0.31 | 0.23 | 0.35 – 0.27 |
| Low | | 00 | | | |
| Normal | – 0.3 mg/dL | 99 | | | |

| | | | | | |
|---------------------------------------------------------|-------------------------------------------------------|-----|--------|---------|------------------|
| High | | 24 | | | |
| Serum Glutamate Pyruvate Transaminase (SGPT) (n= 134) | | | 34.19 | 30.08 | 39.33 – 29.05 |
| Low | | 00 | | | |
| Normal | 0 – 45 IU/L | 121 | | | |
| High | | 13 | | | |
| Serum Glutamic-Oxaloacetic Transaminase (SGOT) (n= 135) | | | 36.68 | 41.43 | 43.73 – 29.63 |
| Low | | 00 | | | |
| Normal | 0 – 35 IU/L | 122 | | | |
| High | | 13 | | | |
| Alkaline Phosphatase (ALP) (n= 98) | | | 66.93 | 35.35 | 74.01 – 59.84 |
| Low | | 18 | | | |
| Normal | 30-120 IU/L | 79 | | | |
| High | | 01 | | | |
| Total Proteins (n= 112) | | | 6.97 | 0.73 | 7.10 – 6.83 |
| Low | | 06 | | | |
| Normal | 3.0 – 8.0 g/dL | 106 | | | |
| High | | 00 | | | |
| Serum Albumin (n= 120) | | | 3.88 | 0.70 | 4.01 – 3.76 |
| Low | | 24 | | | |
| Normal | 40 – 60 g/L | 95 | | | |
| High | | 01 | | | |
| Creatine Kinase-Myocardial Band (CK-MB) (n= 42) | | | 41.59 | 89.62 | 69.51 – 13.66 |
| Low | | 02 | | | |
| Normal | 5 – 25 IU/L | 20 | | | |
| High | | 20 | | | |
| Serum Ferritin (n= 54) | | | 246.34 | 326.73 | 335.52 – 157.16 |
| Low | | 06 | | | |
| Normal | Male: 30.3 to 565.7 ng/mL Female: 14.7 to 205.1 ng/mL | 34 | | | |
| High | | 14 | | | |
| Serum Lactate Dehydrogenase (LDH) (n= 78) | | | 530.73 | 754.58 | 700.86 – 360.60 |
| Low | | 00 | | | |
| Normal | Male: 135 – 225 IU/L Female: 135 – 214 IU/L | 15 | | | |
| High | | 63 | | | |
| Interleukin-6 (IL-6) (n= 21) | | | 956.58 | 1722.50 | 1740.65 – 172.51 |
| Low | | 00 | | | |
| Normal | 0 – 7 pg/mL | 07 | | | |

| | | | | | |
|---------------------------------------|------------------------------------------------------------------------------------|-----|--------|-------|----------------|
| High | | 14 | | | |
| D-Dimer (n= 37) | | | 1.59 | 2.65 | 2.47 – 0.71 |
| Low | | 00 | | | |
| Normal | < 0.50 | 14 | | | |
| High | | 24 | | | |
| Renal Function Tests | | | | | |
| Serum Creatinine (n= 135) | | | 1.27 | 0.87 | 1.42 – 1.13 |
| Low | | 00 | | | |
| Normal | Male: 0.74 – 1.35 mg/dL Female: 0.59 – 1.04 mg/dL | 130 | | | |
| High | | 05 | | | |
| Serum Urea (n= 124) | | | 34.68 | 38.94 | 41.60 – 27.76 |
| Low | | 00 | | | |
| Normal | Male: 6 – 21 mg/dL Female: 8 – 24 mg/dL | 70 | | | |
| High | | 54 | | | |
| Serum Uric Acid (n= 101) | | | 5.48 | 3.08 | 6.09 – 4.87 |
| Low | | 28 | | | |
| Normal | 3.5 – 7.2 mg/dL | 64 | | | |
| High | | 09 | | | |
| Serum Sodium (n= 136) | | | 135.92 | 6.58 | 137.03- 134.80 |
| Low | | 62 | | | |
| Normal | 135 – 145 mmol/L | 67 | | | |
| High | | 07 | | | |
| Serum Potassium (n= 136) | | | 3.84 | 0.53 | 3.93 – 3.75 |
| Low | | 35 | | | |
| Normal | 3.5 – 5.2 mmol/L | 98 | | | |
| High | | 03 | | | |
| Hematological Parameters | | | | | |
| Haemoglobin (n = 137) | | | 13.08 | 2.35 | 13.48 – 12.68 |
| Low | | 49 | | | |
| Normal | Male: 13.5 – 17.5 g/dL Female: 12.0 – 16.0 g/dL | 88 | | | |
| High | | 00 | | | |
| Red Blood Cell (RBC) Count (n= 81) | | | 4.97 | 0.90 | 5.17 – 4.77 |
| Low | | 04 | | | |
| Normal | Male: 4.3 – 5.9 million/mm ³ Female: 3.5 – 5.5 million/ mm ³ | 68 | | | |
| High | | 09 | | | |
| White Blood Cell (WBC) Count (n= 134) | | | 5.99 | 3.52 | 6.60 – 5.39 |
| Low | | 07 | | | |

| | | | | | |
|----------------------------------------|-------------------------------------|-----|--------|-------|-----------------|
| Normal | 4,500 – 11,000/mm ³ | 117 | | | |
| High | | 10 | | | |
| Neutrophil to Lymphocyte Ratio (n= 52) | | | 2.33 | 0.18 | 2.39 – 2.29 |
| Low | | 00 | | | |
| Normal | 0.78 – 3.53 | 52 | | | |
| High | | 00 | | | |
| Platelet Count (n= 140) | | | 246.25 | 72.19 | 258 – 234.19 |
| Low | | 07 | | | |
| Normal | 1,50,000 – 4,00,000/mm ³ | 133 | | | |
| High | | 00 | | | |
| Fasting Blood Sugar Level (n= 31) | | | 129.26 | 41.74 | 144.57 – 113.95 |
| Low | | 00 | | | |
| Normal | 70 – 99 mg/dL | 28 | | | |
| High | | 03 | | | |

TABLE 7: Laboratory parameters of hospitalized Omicron cases

Note: The comparison of laboratory parameters between survived and dead cases could not be calculated statistically as the numbers were low.

Based on the National Early Warning Score (NEWS), patients were classified as having low scores (NEWS 1-4), medium scores (NEWS of 5-6), and high scores (NEWS > 7). Of the 158 cases, 89.24% had a score of 1-4 (low score), and 8.86% had a score between 5-8. Figure 5 and Table 8 show an analysis of the NEWS versus the Omicron variant. The mean NEWS was 2.71 (standard deviation = 2.19, 95% CI = 2.36 to 3.05).




FIGURE 5: Mosaic plot showing National Early Warning Score (NEWS) versus Omicron variant

NEWS - National Early Warning Score

| Test | Chi-Square (χ^2) | Prob>ChiSq (p-value) |
|------------------|-------------------------|----------------------|
| Likelihood Ratio | 9.887 | 0.1295 |
| Pearson | 7.150 | 0.3072 |

TABLE 8: Chi-square test results for goodness of fit showing the relationship between National Early Warning Score (NEWS) versus Omicron variant

No systemic involvement was seen in 64.56% of the cases, while in 35.44% of cases, one or more organ systems were involved. The gastrointestinal and hepatobiliary system was most commonly affected (55.4%), followed by the cardiac system (50%), central nervous system (10.7%), renal system (8.93%), and hematological system (8.93%). Sepsis was seen in 17.9% of cases. For 82 cases, chest X-ray findings were available, of which 77 (93.90%) cases had normal X-Ray findings, whereas five (6.10%) cases had abnormal findings. Of these five cases, two (40%) had pulmonary infiltrates, and three (60%) had evidence of pulmonary oedema. These abnormal findings were seen in cases that succumbed to the disease.

Out of 158 cases, 146 (92.41%) cases recovered with conservative treatment, and 12 (7.59%) cases required additional oxygen therapy. Among those requiring oxygen therapy, 41.67% of cases required invasive ventilation for six to 12 hours. Of the 82 cases admitted, 48.78% were hospitalized for five to nine days.

Discussion

The most recently discovered novel SARS-CoV-2 variant, the Omicron variant, has a much higher effective reproduction number than the Delta variant (3.6 to 4.2 times) and a shorter incubation period. Among all the VOCs detected to date, the Omicron variant possesses the highest number of mutations in its genome, with 32 mutations in its spike protein. Mutations in the spike protein like Q493R, T478K, and N501Y bind to the host cell's angiotensin-converting enzyme 2 (ACE2) receptors with higher affinity than the wild type and other VOCs. Similarly, mutations like H655Y, N679K, and P681H increase cleavage activity by host furin. Such mutations in the spike protein led to increased infectivity and transmissibility [8,4].

The present study suggests that Omicron cases suffered from mild disease with 91.14% of cases having the illness for less than five days. Around 89.24% of cases had a NEWS between 1 to 4 suggesting a good prognosis. More than 90% of cases showed no lung involvement and recovered with conservative treatment. Death due to Omicron infection was seen in 11.5% of cases with most deaths concentrated in the population 60 years and older and those with comorbidities. Our results are consistent with earlier studies in South Africa that suggested a significant reduction in pathogenicity, severity, and mortality rates of the disease during the Omicron wave [9-11]. Similar findings have also been reported in countries such as the United States, France, South Korea, Japan [12-15], and China [8] where both the vaccination coverage and population infection were quite high. However, in the present study, the number of cases was small. As a result, the numbers under different subgroups were even smaller. With increasing numbers of cases presenting with no symptoms or requiring no hospital admission, clinical data in such cases became less available.

Transmembrane serine proteases 2 (TMPRSS2) facilitate viral entry into the host cell. The wild-type variant and other VOCs efficiently utilize this cell surface fusion pathway to enter the host cell. However, in the case of Omicron, the variant is inefficient in using this pathway. Studies indicate that Omicron depends on cathepsins and enters the host cell primarily through the endosomal pathway. The co-expression of ACE2 and cathepsins are abundant in the upper respiratory tract, explaining the increased replication of Omicron in bronchi than in the lungs. Therefore, in Omicron infection, there is reduced lung pathology and diminished pro-inflammatory responses [16]. This property probably explains the reduced disease severity, the reduced need for oxygen and hospital admission, and better survival outcomes in the Omicron cases compared to other VOCs. Our results are consistent with these findings, wherein 93.90% of cases had no lung involvement and 92.41% recovered with conservative treatment without any additional oxygen requirement.

Since the Omicron variant has acquired numerous mutations in its spike protein, particularly in its receptor-binding domain (RBD), this has increased the likelihood of reduced efficacy of the neutralizing antibodies on Omicron. Various studies have shown that Omicron partially or completely escapes neutralization by antibodies present in convalescent sera [17,18] and vaccinated individuals [19-21], thus suggesting evasion of natural and vaccine-induced immunity. Also, monoclonal antibodies, either clinically approved or in development for treatment, have completely failed to neutralize Omicron [22,23,18]. Mutations like E484A and K417N dodge the neutralizing antibodies, eventually resulting in an increased ability of immune escape [4]. Therefore, this probably explains the increased frequency of breakthrough infections and reinfection incidents during the Omicron wave. Besides the antibody-mediated immunity, studies have shown that T-cell responses to the Omicron variant are primarily preserved, and T-cell escape is minimal compared to other VOCs. Also, the booster vaccine doses enhance T-cell responses [24]. In the present study, the vaccination rate in the population under investigation was good, and it could have potentially contributed to the reduced severity of the disease. Therefore, good vaccination coverage is desirable for effective protection against severe disease [25].

The present study could not compare the differences in laboratory parameters between the survived and deceased cases due to the unavailability of investigation results for brought-in dead cases and a low number of in-hospital deaths. This fact limited our ability to draw definitive conclusions about the relationship between these laboratory parameters and the survival outcomes.

Conclusions

To conclude, the present study described the baseline characteristics of laboratory-confirmed Omicron variant cases in Pune, Maharashtra. Our analysis indicates Omicron causes a mild disease, with a reduced need for hospital admission, and a lower need for oxygen therapy. The overall lowered disease severity reflects the contribution of attenuated intrinsic virulence of the virus as well as the impact of prior immunity due to natural infection and/or vaccination. Vaccine breakthrough infections were commonly seen. Additional studies will continue to be essential in understanding the evolution of current and future variants in populations with a diverse immunological landscape.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee, B. J. Govt. Medical College & Sassoon General Hospitals, Pune 1 issued approval BJGMC/IEC/Pharmac/ND-Dept 0721233-233, dated 15-09-2021. The Institutional Ethics Committee has unanimously approved your project topic. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. World Health Organization . (2021). Accessed: 7th December 2022: [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern) .
2. Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States. World Health Organization. (2022). Accessed: 7th December 2022: [https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-\(b.1.1.529\)-technical-brief-and-priority-acti....](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-acti....)
3. COVID-19 Weekly Epidemiological Update. 106th ed. World Health Organization . (2022). Accessed: 7th December 2022: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---24-august-2022>.
4. Khandia R, Singhal S, Alqahtani T, et al.: Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. *Environ Res.* 2022, 209:112816. [10.1016/j.envres.2022.112816](https://doi.org/10.1016/j.envres.2022.112816)
5. Petersen MS, Í Kongsstovu S, Eliassen EH, et al.: Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands. *Int J Infect Dis.* 2022, 122:636-43. [10.1016/j.ijid.2022.07.005](https://doi.org/10.1016/j.ijid.2022.07.005)
6. INSACOG Weekly Bulletin No. 29. Department of Biotechnology . (2022). Accessed: 7th December 2022: <https://dbtindia.gov.in/sites/default/files/INSACOG%20WEEKLY%20BULLETIN%2010-01-2022.pdf> .
7. Coronavirus Pandemic (COVID-19). Our World in Data . (2022). Accessed: 25th August 2022: <https://ourworldindata.org/covid-vaccinations?country=IND>.
8. Zhang J, Chen N, Zhao D, Zhang J, Hu Z, Tao Z: Clinical Characteristics of COVID-19 Patients Infected by the Omicron Variant of SARS-CoV-2. *Front Med (Lausanne)*. 2022, 9:912367. [10.3389/fmed.2022.912367](https://doi.org/10.3389/fmed.2022.912367)
9. Jassat W, Abdool Karim SS, Mudara C, et al.: Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. *Lancet Glob Health.* 2022, 10:e961-9. [10.1016/S2214-109X\(22\)00114-0](https://doi.org/10.1016/S2214-109X(22)00114-0)
10. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B: Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. *JAMA.* 2022, 327:583-4. [10.1001/jama.2021.24868](https://doi.org/10.1001/jama.2021.24868)
11. Wolter N, Jassat W, Walaza S, et al.: Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. *Lancet.* 2022, 399:437-46. [10.1016/S0140-6736\(22\)00017-4](https://doi.org/10.1016/S0140-6736(22)00017-4)
12. Modes ME, Directo MP, Melgar M, et al.: Clinical characteristics and outcomes among adults hospitalised with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant predominance — one hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. *MMWR Morb Mortal Wkly Rep.* 2022, 71:217-23. [10.15585/mmwr.mm7106e2](https://doi.org/10.15585/mmwr.mm7106e2)
13. Houhamdi L, Gautret P, Hoang VT, Fournier PE, Colson P, Raoult D: Characteristics of the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December 2021. *J Med Virol.* 2022, 94:2290-5. [10.1002/jmv.27613](https://doi.org/10.1002/jmv.27613)
14. Kim MK, Lee B, Choi YY, et al.: Clinical characteristics of 40 patients infected with the SARS-CoV-2 Omicron variant in Korea. *J Korean Med Sci.* 2022, 37:e31. [10.3346/jkms.2022.37.e31](https://doi.org/10.3346/jkms.2022.37.e31)
15. Suzuki K, Ichikawa T, Suzuki S, Tanino Y, Kakinoki Y: Clinical characteristics of the severe acute respiratory syndrome coronavirus 2 omicron variant compared with the delta variant: a retrospective case-control study of 318 outpatients from a single sight institute in Japan. *PeerJ.* 2022, 10:e13762. [10.7717/peerj.13762](https://doi.org/10.7717/peerj.13762)
16. Hui KP, Ho JC, Cheung MC, et al.: SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. *Nature.* 2022, 603:715-20. [10.1038/s41586-022-04479-6](https://doi.org/10.1038/s41586-022-04479-6)
17. Zhang X, Wu S, Wu B, et al.: SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. *Signal Transduct Target Ther.* 2021, 6:430. [10.1038/s41392-021-00852-5](https://doi.org/10.1038/s41392-021-00852-5)
18. Planas D, Veyer D, Baidaliuk A, et al.: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature.* 2021, 596:276-80. [10.1038/s41586-021-03777-9](https://doi.org/10.1038/s41586-021-03777-9)
19. Dejnirattisai W, Shaw RH, Supasa P, et al.: Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. *Lancet.* 2022, 399:234-6. [10.1016/S0140-6736\(21\)02844-0](https://doi.org/10.1016/S0140-6736(21)02844-0)
20. Lu L, Mok BW, Chen LL, et al.: Neutralization of severe acute respiratory syndrome coronavirus 2 Omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients. *Clin Infect Dis.* 2022, 75:e822-6. [10.1093/cid/ciab1041](https://doi.org/10.1093/cid/ciab1041)
21. Burki TK: Omicron variant and booster COVID-19 vaccines. *Lancet Respir Med.* 2022, 10:e17. [10.1016/S2213-2600\(21\)00559-2](https://doi.org/10.1016/S2213-2600(21)00559-2)
22. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL: Neutralizing monoclonal antibodies for treatment of COVID-19. *Nat Rev Immunol.* 2021, 21:382-93. [10.1038/s41577-021-00542-x](https://doi.org/10.1038/s41577-021-00542-x)
23. Ai J, Zhang H, Zhang Y, et al.: Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. *Emerg Microbes Infect.* 2022, 11:337-43. [10.1080/22221751.2021.2022440](https://doi.org/10.1080/22221751.2021.2022440)
24. Naranbhai V, Nathan A, Kaseke C, et al.: T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. *Cell.* 2022, 185:1041-1051.e6. [10.1016/j.cell.2022.01.029](https://doi.org/10.1016/j.cell.2022.01.029)
25. Goyal L, Zapata M, Ajmera K, Chaurasia P, Pandit R, Pandit T: A Hitchhiker's Guide to worldwide COVID-19 vaccinations: a detailed review of monovalent and bivalent vaccine schedules, COVID-19 vaccine side effects, and effectiveness against Omicron and Delta variants. *Cureus.* 2022, 14:e29837. [10.7759/cureus.29837](https://doi.org/10.7759/cureus.29837)